These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36429133)

  • 1. In Vitro Veritas: From 2D Cultures to Organ-on-a-Chip Models to Study Immunogenic Cell Death in the Tumor Microenvironment.
    Krysko DV; Demuynck R; Efimova I; Naessens F; Krysko O; Catanzaro E
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy.
    Xu W; Liu W; Yang J; Lu J; Zhang H; Ye D
    Immunol Rev; 2024 Jan; 321(1):181-198. PubMed ID: 37403660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic cell death in cancer therapy: Present and emerging inducers.
    Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
    J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Nano-Biomaterials for Cancer Therapy via Inducing Enhanced Immunogenic Cell Death.
    Chen Q; Li C; Wang Q
    Small Methods; 2023 May; 7(5):e2201457. PubMed ID: 36703555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive oxygen species of tumor microenvironment: Harnessing for immunogenic cell death.
    Malla R; Kumari S; Ganji SP; Srilatha M; Nellipudi HR; Nagaraju GP
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189154. PubMed ID: 39019409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective.
    Kashefizadeh A; Kazemizadeh H
    Clin Transl Oncol; 2023 Feb; 25(2):316-322. PubMed ID: 36180811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
    Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
    Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor-on-a-Chip.
    Li W; Zhou Z; Zhou X; Khoo BL; Gunawan R; Chin YR; Zhang L; Yi C; Guan X; Yang M
    Adv Healthc Mater; 2023 Jul; 12(18):e2202609. PubMed ID: 36917657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
    Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
    J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
    Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
    Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor.
    Jiang Q; Zhang C; Wang H; Peng T; Zhang L; Wang Y; Han W; Shi C
    Front Oncol; 2019; 9():1196. PubMed ID: 31781498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
    Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D Tumor Models and Their Use for the Testing of Immunotherapies.
    Boucherit N; Gorvel L; Olive D
    Front Immunol; 2020; 11():603640. PubMed ID: 33362787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
    Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
    Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products.
    Zhang LL; Zhang DJ; Shi JX; Huang MY; Yu JM; Chen XJ; Wei X; Zou L; Lu JJ
    Phytomedicine; 2024 Sep; 132():155828. PubMed ID: 38905847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomimetic Active Materials Guided Immunogenic Cell Death for Enhanced Cancer Immunotherapy.
    Huang G; Liu L; Pan H; Cai L
    Small Methods; 2023 May; 7(5):e2201412. PubMed ID: 36572642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers.
    Shi F; Huang X; Hong Z; Lu N; Huang X; Liu L; Liang T; Bai X
    Cancer Lett; 2023 May; 562():216167. PubMed ID: 37031916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.